News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,323 Results
Type
Article (43231)
Company Profile (297)
Press Release (678795)
Multimedia
Podcasts (83)
Webinars (12)
Section
Business (211303)
Career Advice (2114)
Deals (36768)
Drug Delivery (109)
Drug Development (83447)
Employer Resources (176)
FDA (16726)
Job Trends (15482)
News (357947)
Policy (34563)
Tag
Academia (2620)
Accelerated approval (5)
Adcomms (21)
Allergies (91)
Alliances (51677)
ALS (94)
Alzheimer's disease (1400)
Antibody-drug conjugate (ADC) (133)
Approvals (16726)
Artificial intelligence (271)
Autoimmune disease (23)
Automation (16)
Bankruptcy (371)
Best Places to Work (11804)
BIOSECURE Act (21)
Biosimilars (113)
Biotechnology (189)
Bladder cancer (78)
Brain cancer (30)
Breast cancer (282)
Cancer (2308)
Cardiovascular disease (186)
Career advice (1771)
Career pathing (31)
CAR-T (156)
Cell therapy (434)
Cervical cancer (20)
Clinical research (67844)
Collaboration (857)
Company closure (1)
Compensation (540)
Complete response letters (26)
COVID-19 (2680)
CRISPR (46)
C-suite (249)
Cystic fibrosis (103)
Data (2227)
Decentralized trials (2)
Denatured (28)
Depression (46)
Diabetes (277)
Diagnostics (6470)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (115)
Drug shortages (28)
Duchenne muscular dystrophy (96)
Earnings (88616)
Editorial (42)
Employer branding (22)
Employer resources (150)
Events (115802)
Executive appointments (739)
FDA (18010)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (762)
Gene editing (112)
Generative AI (22)
Gene therapy (321)
GLP-1 (757)
Government (4812)
Grass and pollen (5)
Guidances (67)
Healthcare (19159)
Huntington's disease (24)
IgA nephropathy (31)
Immunology and inflammation (125)
Indications (30)
Infectious disease (2823)
Inflammatory bowel disease (142)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (329)
IPO (16824)
IRA (47)
Job creations (4098)
Job search strategy (1511)
Kidney cancer (10)
Labor market (38)
Layoffs (500)
Leadership (18)
Legal (8480)
Liver cancer (77)
Lung cancer (323)
Lymphoma (157)
Machine learning (7)
Management (59)
Manufacturing (322)
MASH (69)
Medical device (13522)
Medtech (13527)
Mergers & acquisitions (20488)
Metabolic disorders (719)
Multiple sclerosis (80)
NASH (17)
Neurodegenerative disease (94)
Neuropsychiatric disorders (29)
Neuroscience (1962)
NextGen: Class of 2025 (6668)
Non-profit (4570)
Now hiring (39)
Obesity (385)
Opinion (236)
Ovarian cancer (76)
Pain (97)
Pancreatic cancer (84)
Parkinson's disease (152)
Partnered (21)
Patents (240)
Patient recruitment (113)
Peanut (50)
People (59525)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (21012)
Phase II (29814)
Phase III (22401)
Pipeline (1217)
Policy (155)
Postmarket research (2702)
Preclinical (8948)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (254)
Rare diseases (398)
Real estate (6295)
Recruiting (68)
Regulatory (23439)
Reports (46)
Research institute (2387)
Resumes & cover letters (362)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (77)
Series A (133)
Series B (85)
Service/supplier (13)
Sickle cell disease (55)
Special edition (15)
Spinal muscular atrophy (154)
Sponsored (30)
Startups (3745)
State (2)
Stomach cancer (14)
Supply chain (70)
Tariffs (45)
The Weekly (53)
Vaccines (717)
Venture capitalists (41)
Weight loss (259)
Women's health (35)
Worklife (16)
Date
Today (154)
Last 7 days (939)
Last 30 days (2675)
Last 365 days (33296)
2025 (10947)
2024 (35872)
2023 (40725)
2022 (51907)
2021 (56495)
2020 (55016)
2019 (47771)
2018 (36061)
2017 (33291)
2016 (32871)
2015 (38781)
2014 (32704)
2013 (27828)
2012 (29909)
2011 (30637)
2010 (28674)
Location
Africa (801)
Alabama (53)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40936)
Australia (6566)
California (6179)
Canada (2041)
China (541)
Colorado (269)
Connecticut (275)
Delaware (151)
Europe (87791)
Florida (916)
Georgia (206)
Idaho (58)
Illinois (552)
India (27)
Indiana (320)
Iowa (11)
Japan (166)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (904)
Massachusetts (4641)
Michigan (222)
Minnesota (394)
Mississippi (2)
Missouri (85)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (64)
New Jersey (1744)
New Mexico (29)
New York (1757)
North Carolina (992)
North Dakota (8)
Northern California (2696)
Ohio (204)
Oklahoma (14)
Oregon (39)
Pennsylvania (1392)
Puerto Rico (12)
Rhode Island (33)
South America (1175)
South Carolina (23)
South Dakota (1)
Southern California (2317)
Tennessee (102)
Texas (916)
United States (23411)
Utah (182)
Virginia (155)
Washington D.C. (63)
Washington State (562)
West Virginia (3)
Wisconsin (57)
722,323 Results for "novartis pharmaceuticals canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Novartis Canada’s statement on CADTH draft recommendations for LEQVIO (inclisiran)
Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran).
March 21, 2024
·
4 min read
Business
Novartis Canada and Clarius Mobile Health Challenge Standard of Care for Psoriatic Arthritis With New Partnership
Novartis Pharmaceuticals Canada Inc. is pleased to announce a partnership with Clarius Mobile Health as part of a dedicated effort to aid in early detection of psoriatic arthritis in Canada.
May 27, 2024
·
4 min read
Press Releases
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH
February 14, 2025
·
8 min read
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Press Releases
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
April 9, 2025
·
5 min read
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
April 10, 2025
·
7 min read
INNODEM NEUROSCIENCES SIGNS A STRATEGIC COMMERCIAL FRAMEWORK AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA INC.
Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).
September 7, 2023
·
4 min read
Press Releases
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura in Canada
April 16, 2025
·
8 min read
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 72,233
Next
